A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Renal Cell Carcinoma
DRUG: SGN-75|DRUG: everolimus
Incidence of adverse events and laboratory abnormalities, Through 1 month post last dose
Best clinical response according to RECIST Version 1.1, Through 1 month post last dose|Progression-free survival, Until disease progression or start of new anticancer treatment, an expected average of 6 months|Overall survival, Until death or study closure, an expected average of 1 year|Blood concentrations of SGN-75 and metabolites, Cycle 1: pre-dose, 30 minutes, and 2, 4, 8, 24, 168, and 336 hours post dose start; pre-dose in subsequent cycles, and 1 month post last dose|Incidence of antitherapeutic antibodies, Pre-dose in most cycles and 1 month post last dose
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.